CN105434681A - Traditional Chinese medicine health-care preparation for reducing blood lipid - Google Patents
Traditional Chinese medicine health-care preparation for reducing blood lipid Download PDFInfo
- Publication number
- CN105434681A CN105434681A CN201510993628.0A CN201510993628A CN105434681A CN 105434681 A CN105434681 A CN 105434681A CN 201510993628 A CN201510993628 A CN 201510993628A CN 105434681 A CN105434681 A CN 105434681A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- parts
- chinese medicine
- treatment
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Abstract
The invention provides a traditional Chinese medicine health-care preparation for reducing blood fat. The preparation is prepared from the following raw materials; rhizoma atractylodis macrocephalae, cortex lycii radicis, prepared rhubarb, leaf of Broadleaf Holly, Fructus Gardeniae and raw hawthorns fruits, and the effects of the medicinal materials are synergized to achieve the functions of strengthening spleen, tonifying qi, drying dampness, inducing diuresis, cooling blood and purging heat, and human body fat metabolism or operation becomes normal, so that the function of relaxing bowels and reducing blood fat can be achieved, and the problem of comprehensively relieving and eliminating hyperlipidemia can be solved. Clinical observation data indicate that the traditional Chinese medicine health-care preparation has a definite regulating effect on cholesterol and triglyceride, and no relapse happens in three months after treatment is stopped. Furthermore, the traditional Chinese medicine health-care preparation strictly accords with the principle of the traditional Chinese medicine formula, does not have toxic or side effect, can be taken for a long time, avoids negative effects caused by western medicine treatment on a body, and sufficiently exerts the splendid traditional Chinese medicine culture, so that prevention and treatment can be taken simultaneously, and equal attention is paid to both maintenance and treatment.
Description
Technical field
The invention belongs to Chinese medicine health-care field, relate to a kind of Health-protection traditional Chinese medicinal preparation for blood fat reducing.
Background technology
Blood fat is the general name of contained lipid in blood, and mainly comprise cholesterol, triglyceride, phospholipid, fatty acid etc., they are important component parts of blood.When lipid metabolism or running make one or more lipids of blood plasma extremely higher than normal value, be called hyperlipemia.The main harm of hyperlipemia causes atherosclerosis, and then cause numerous relevant diseases, and wherein modal a kind of fatal disease is exactly coronary heart disease.
About the diagnostic criteria of hyperlipemia, at present international and domesticly there is no unified method.Previously think total cholesterol density of blood plasma >5.17mmol/L(200mg/dl) can hypercholesterolemia be decided to be, blood plasma triacylglycerol concentration >2.3mmol/L(200mg/dl) be hypertriglyceridemia.Various places due to the factors such as the different and difference of method of testing that adopts of survey crowd, the hyperlipemia diagnostic criteria of formulating differs.But in order to prevent and treat atherosclerosis and coronary heart disease, suitable blood plasma cholesterol level should decide according to the risk of patient's generation in future cardiovascular and cerebrovascular disease, and occurrence risk is higher, and suitable blood plasma cholesterol level should be lower.General by adult's Diagnostic Value of Fasting Serum T-CHOL more than 5.72mmolL, triglyceride, more than 1.70mmolL, is diagnosed as hyperlipemia.
For the treatment of hyperlipemia, mainly by strengthening taking exercise, to strengthen cardio-pulmonary function, to improve insulin resistant and glucose tolerance, but also can lose weight, reduce blood plasma triacylglycerol and cholesterol levels, raises HDL cholesterol level.At present, Statins and resinae is had based on what reduce serum total cholesterol and LDL-C.The special class of shellfish and nicotinic acid class is had based on the medicine reducing serum triacylglycerol.
Although the factor of hyperlipidemia is varied, but think through our long-term research, the main flow problem of hyperlipidemia is caused to be insufficiency of the spleen and heat in blood, therefore, treatment hyperlipidemia should expel the heat-evil and start with from invigorating the spleen and benefiting QI, removing heat from blood, make body fat metabolism or running be tending towards normal by regulating, thus realize the function of purging FU-organs blood fat reducing, the problem of full relief, releasing hyperlipidemia.
Summary of the invention
The object of the invention is based on above-mentioned research, a kind of Health-protection traditional Chinese medicinal preparation for blood fat reducing is provided.
Chinese medicine preparation of the present invention selects the Rhizoma Atractylodis Macrocephalae, Cortex Lycii, Radix et Rhizoma Rhei (processed), Folium Ilicis, Fructus Gardeniae, Fructus Crataegi to be that raw material carries out compatibility, effect of each medicine is produced collaborative, gathers that invigorating the spleen and benefiting QI, dampness diuretic, removing heat from blood expel the heat-evil, the function of purging FU-organs blood fat reducing altogether.
The Rhizoma Atractylodis Macrocephalae, bitter, sweet, temperature.Return spleen, stomach warp.Function cures mainly: invigorating the spleen and benefiting QI, dampness diuretic.The present invention take the Rhizoma Atractylodis Macrocephalae as monarch drug, by invigorating the spleen and benefiting QI, dampness diuretic to reduce blood fat.Cortex Lycii, sweet, cold.Return lung, liver, kidney channel.Function cures mainly: removing heat from blood removes and steams, lung heat clearing pathogenic fire reducing.The present invention take Cortex Lycii as ministerial drug, by removing heat from blood except steaming, lung heat clearing pathogenic fire reducing are to separate dehematize poison.Radix et Rhizoma Rhei (processed), it is cold in nature, bitter in the mouth.Effect: heat and toxic materials clearing away, eliminating fire and detoxication, clearing away heat and cooling blood, blood stasis dispelling stimulates the menstrual flow.Folium Ilicis, sweet; Bitter; Cold.Enter liver, lung, stomach.Function cures mainly
:wind and heat dispersing; Improving eyesight is promoted the production of body fluid.The present invention is with Radix et Rhizoma Rhei (processed), Folium Ilicis altogether for adjuvant drug, and upper, middle and lower of advocating three is burnt, and logical intestinal, to rush down its internal organs heat, removing heat from blood to separate its dysentery, removing blood stasis with its all warp logical, helps monarch-minister drug a helping hand.Fructus Gardeniae, nature and flavor are bitter, cold.GUIXIN, lung, tri-jiao channel.Effect; Heat clearing away, pathogenic fire purging, removing heat from blood.Fructus Crataegi, sour in the mouth is sweet, slightly warm in nature, returns spleen, stomach, Liver Channel.Function: blood circulation promoting and blood stasis dispelling, vessel softening, reduction blood fat, promoting digestion and invigorating the stomach.The present invention is using Fructus Gardeniae, Fructus Crataegi as making medicine, and Fructus Gardeniae further makes blood fat, heat in blood, blood poison just get rid of from two, the poison of the poison of Fructus Crataegi eliminating indigested food, the strongly fragrant poison of circulation of qi promoting, loose blood stasis.Full side makes a concerted effort, and invigorating the spleen and benefiting QI, dampness diuretic, detoxicating expel the heat-evil, and make body fat metabolism or running be tending towards normal, thus realize the function of purging FU-organs blood fat reducing, the problem of full relief, releasing hyperlipidemia.
Chinese medicine preparation of the present invention carries out proportioning by following weight portion: Rhizoma Atractylodis Macrocephalae 28-38 part, Cortex Lycii 20-27 part, Radix et Rhizoma Rhei (processed) 13-18 part, Folium Ilicis 13-18 part, Fructus Gardeniae 4-10 part, Fructus Crataegi 3-10 part.
Optimum ratio: Rhizoma Atractylodis Macrocephalae 30-32 part, Cortex Lycii 23-26 part, Radix et Rhizoma Rhei (processed) 14-16 part, Folium Ilicis 14-16 part, Fructus Gardeniae 6-9 part, Fructus Crataegi 6-8 part.
Optimum proportioning: the Rhizoma Atractylodis Macrocephalae 30 parts, Cortex Lycii 25 parts, Radix et Rhizoma Rhei (processed) 15 parts, Folium Ilicis 15 parts, Fructus Gardeniae 8 parts, Fructus Crataegi 7 parts.
The oral preparations that Health-protection traditional Chinese medicinal preparation of the present invention can be prepared into by the common process of pharmaceutics and adjuvant, as soft capsule, capsule, granule, tablet or oral liquid etc.
Be described below by the effect of clinical data to Health-protection traditional Chinese medicinal preparation blood fat reducing of the present invention.
1, clinical observation object: select hyperlipemic patients 20 example, man, female half and half, the age 40-75 year.
2, clinical symptoms: dizziness, spiritlessness and weakness, insomnia forgetfulness, numb limbs and tense tendons, uncomfortable in chest, cardiopalmus etc.Health check-up chemical examination blood indices: serum total cholesterol is more than 5.72mmolL, and triglyceride is more than 1.70mmolL.
3, Therapeutic Method: take Tablets medicine (Rhizoma Atractylodis Macrocephalae ground osteocomma), specification: 0.6g/ sheet * 90/bottle/box.Usage: each 5 sooner or later, warm water is directly taken after mixing it with water.The course for the treatment of: cycle in March 1, overview 3 cycle.
4, measurement result: clinical observation shows, some clinical symptoms such as uncomfortable phenomenons such as dizziness, spiritlessness and weakness, insomnia forgetfulness, numb limbs and tense tendons, uncomfortable in chest, cardiopalmus substantially disappear or obviously alleviate, and every Index for examination is in table 1.
As can be seen from table 1 detection data we, Health-protection traditional Chinese medicinal preparation of the present invention has clear and definite regulating action for cholesterol, triglyceride, and stop treatment latter 3 months in without rebound phenomenon.
The present invention is strictly by motherland's medical science formulation principle, and no side effects, can eat for a long time, avoids the negative effect that western medicine causes health, has given full play to motherland's medical Culture of China's brilliance simultaneously, and treatment and prevention, foster treatment are laid equal stress on.
Detailed description of the invention
Below by specific embodiment, the proportioning raw materials of medicine of the present invention, preparation and usage side are described further.
The preparation of embodiment 1, granules medicine
Proportioning raw materials: the Rhizoma Atractylodis Macrocephalae 30 parts, Cortex Lycii 25 parts, Radix et Rhizoma Rhei (processed) 15 parts, Folium Ilicis 15 parts, Fructus Gardeniae 8 parts, Fructus Crataegi 7 parts.
Preparation technology: prepare the common process of granule by pharmaceutics and adjuvant is prepared from.Specification: 5g/ bag.
Usage and dosage: 2 times on the one, once take 1 bag.The course for the treatment of: in the cycle in March 1, serve on for 3 cycles.
The preparation of embodiment 2, capsule medicine
Proportioning raw materials: the Rhizoma Atractylodis Macrocephalae 28 parts, Cortex Lycii 20 parts, Radix et Rhizoma Rhei (processed) 13 parts, Folium Ilicis 13 parts, Fructus Gardeniae 4 parts, Fructus Crataegi 3 parts.
Preparation technology: prepare the common process of capsule by pharmaceutics and adjuvant is prepared from.Every 0.4g;
Using method: 2 times on the one, once take 4.The course for the treatment of: in the cycle in March 1, serve on for 3 cycles.。
The preparation of embodiment 3, tablet medicine
Proportioning raw materials: the Rhizoma Atractylodis Macrocephalae 38 parts, Cortex Lycii 27 parts, Radix et Rhizoma Rhei (processed) 18 parts, Folium Ilicis 18 parts, Fructus Gardeniae 10 parts, Fructus Crataegi 10 parts.
Preparation technology: prepare the common process of tablet by pharmaceutics and adjuvant is prepared from.Every sheet 0.6g.
Using method: 2 times on the one, once take 5.The course for the treatment of: in the cycle in March 1, serve on for 3 cycles.
The preparation of embodiment 4, soft capsule medicine
Proportioning raw materials: the Rhizoma Atractylodis Macrocephalae 32 parts, Cortex Lycii 26 parts, Radix et Rhizoma Rhei (processed) 16 parts, Folium Ilicis 16 parts, Fructus Gardeniae 9 parts, Fructus Crataegi 8 parts.
Preparation technology: prepare the common process of soft capsule by pharmaceutics and adjuvant is prepared from.Every 0.05g;
Using method: using method: 2 times on the one, once take 5.The course for the treatment of: in the cycle in March 1, serve on for 3 cycles.
The preparation of embodiment 5, oral liquid
Proportioning raw materials: the Rhizoma Atractylodis Macrocephalae 30 parts, Cortex Lycii 23 parts, Radix et Rhizoma Rhei (processed) 14 parts, Folium Ilicis 14 parts, Fructus Gardeniae 6 parts, Fructus Crataegi 6 parts.
Preparation technology: prepare the common process of oral liquid by pharmaceutics and adjuvant is prepared from.Every bottle of 10ml;
Using method: 2 times on the one, once take 20ml.The course for the treatment of: in the cycle in March 1, serve on for 3 cycles.
In the various embodiments described above, each proportioning raw materials is all with parts by weight.
Claims (4)
1. for a Health-protection traditional Chinese medicinal preparation for blood fat reducing, be with the Rhizoma Atractylodis Macrocephalae, Cortex Lycii, Radix et Rhizoma Rhei (processed), Folium Ilicis, Fructus Gardeniae, Fructus Crataegi for crude drug, be prepared into oral preparations by the technique of the routine of pharmaceutics and adjuvant.
2. as claimed in claim 1 for the Health-protection traditional Chinese medicinal preparation of blood fat reducing, it is characterized in that: described each crude drug carries out proportioning by following weight portion: Rhizoma Atractylodis Macrocephalae 28-38 part, Cortex Lycii 20-27 part, Radix et Rhizoma Rhei (processed) 13-18 part, Folium Ilicis 13-18 part, Fructus Gardeniae 4-10 part, Fructus Crataegi 3-10 part.
3. as claimed in claim 1 for the Health-protection traditional Chinese medicinal preparation of blood fat reducing, it is characterized in that: described each crude drug carries out proportioning by following weight portion: Rhizoma Atractylodis Macrocephalae 30-32 part, Cortex Lycii 23-26 part, Radix et Rhizoma Rhei (processed) 14-16 part, Folium Ilicis 14-16 part, Fructus Gardeniae 6-9 part, Fructus Crataegi 6-8 part.
4. as claimed in claim 1 for the Health-protection traditional Chinese medicinal preparation of blood fat reducing, it is characterized in that: described each crude drug carries out proportioning by following weight portion: the Rhizoma Atractylodis Macrocephalae 30 parts, Cortex Lycii 25 parts, Radix et Rhizoma Rhei (processed) 15 parts, Folium Ilicis 15 parts, Fructus Gardeniae 8 parts, Fructus Crataegi 7 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510993628.0A CN105434681A (en) | 2015-12-24 | 2015-12-24 | Traditional Chinese medicine health-care preparation for reducing blood lipid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510993628.0A CN105434681A (en) | 2015-12-24 | 2015-12-24 | Traditional Chinese medicine health-care preparation for reducing blood lipid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105434681A true CN105434681A (en) | 2016-03-30 |
Family
ID=55545612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510993628.0A Pending CN105434681A (en) | 2015-12-24 | 2015-12-24 | Traditional Chinese medicine health-care preparation for reducing blood lipid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105434681A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853702A (en) * | 2005-04-26 | 2006-11-01 | 杨吉星 | Chinese medicinal preparation for lowering blood sugar, blood fat and blood pressure, improving blood flow and immune and its making method |
| CN101731391A (en) * | 2009-12-18 | 2010-06-16 | 苏州瑞得符生物科技有限公司 | Sanqing broadleaf holly leaf |
| CN102106993A (en) * | 2011-02-17 | 2011-06-29 | 上海方心健康科技发展有限公司 | Chinese medicinal composition for treating fatty liver and preparation method thereof |
| CN103734426A (en) * | 2013-12-31 | 2014-04-23 | 青岛恒波仪器有限公司 | Health-care cornus officinalis tea capable of improving immunity and preparation method of tea |
| CN104207129A (en) * | 2014-09-12 | 2014-12-17 | 兰州古驰生物科技有限公司 | Health traditional Chinese medicine preparation for regulating sub-health of heart and blood vessels |
-
2015
- 2015-12-24 CN CN201510993628.0A patent/CN105434681A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853702A (en) * | 2005-04-26 | 2006-11-01 | 杨吉星 | Chinese medicinal preparation for lowering blood sugar, blood fat and blood pressure, improving blood flow and immune and its making method |
| CN101731391A (en) * | 2009-12-18 | 2010-06-16 | 苏州瑞得符生物科技有限公司 | Sanqing broadleaf holly leaf |
| CN102106993A (en) * | 2011-02-17 | 2011-06-29 | 上海方心健康科技发展有限公司 | Chinese medicinal composition for treating fatty liver and preparation method thereof |
| CN103734426A (en) * | 2013-12-31 | 2014-04-23 | 青岛恒波仪器有限公司 | Health-care cornus officinalis tea capable of improving immunity and preparation method of tea |
| CN104207129A (en) * | 2014-09-12 | 2014-12-17 | 兰州古驰生物科技有限公司 | Health traditional Chinese medicine preparation for regulating sub-health of heart and blood vessels |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110787233B (en) | Liver-protecting traditional Chinese medicine composition, extract and pharmaceutical application thereof | |
| CN1475229A (en) | Antifatigue compound Chinese medicine prescription and its preparation method | |
| CN105727145A (en) | Traditional Chinese medicine drug for treating spleen deficiency phlegm-dampness syndrome type hyperlipidaemia | |
| CN105560779B (en) | The compound preparation and application thereof for preventing and treating non-alcohol fatty liver | |
| CN103800352B (en) | Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof | |
| CN102641469B (en) | Medicinal composition for preventing or treating nonalcoholic steatohepatitis | |
| CN104857436B (en) | Traditional Chinese medicine compound composition with resisting liver cancer activity and its preparation method and application | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN105434681A (en) | Traditional Chinese medicine health-care preparation for reducing blood lipid | |
| CN104826049B (en) | A kind of herbal cuisine and its preparation method and application of prevention atherosclerosis | |
| CN102247572B (en) | Medicament for treating hyperlipidemia | |
| CN103301220B (en) | Traditional Chinese medicine for treating hyperlipidemia and preparation method thereof | |
| CN103223143B (en) | Traditional Chinese medicine composition for treating simple obesity, and preparation method and application thereof | |
| CN103316106A (en) | Danshan fat reducing granules and preparation method thereof | |
| CN102406906A (en) | Traditional Chinese medicine composition for treating acute hepatitis B | |
| LU504091B1 (en) | Traditional chinese medicine preparation for enhancing antiviral efficacy of entecavir combined with chb and nafld, preparation method thereof and combined therapeutic drug | |
| CN104888017A (en) | Medicine for treating hepatitis B | |
| CN105748669B (en) | Traditional Chinese medicine composition for preventing and treating alcoholic fatty liver | |
| CN103006837B (en) | Composition for reducing blood fat | |
| CN104001044A (en) | Traditional Chinese medicine composition treating hyperlipidemia | |
| CN103768289A (en) | Portulaca oleracea oral liquid for treating non-alcoholic fatty liver and preparation method thereof | |
| CN103610855A (en) | Traditional Chinese medicine composition for treating children obesity | |
| CN105194528A (en) | Medicine composition for treating hyperlipidemia and viral hepatitis at same time, preparing method thereof and application thereof | |
| CN103656519A (en) | Traditional Chinese medicine preparation for curing neurasthenia as well as preparation method and application thereof | |
| CN115944700A (en) | Traditional Chinese medicine composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160330 |
|
| WD01 | Invention patent application deemed withdrawn after publication |